Acadian Asset Management
NVET

Acadian Asset Management’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

Acadian Asset Management’s Portfolio NVET Stock Details NVET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-564
Closed -$2K – 1913
2016
Q4 		$2K Hold
564
– – ﹤0.01% 1578
2016
Q3 		$2K Hold
564
– – ﹤0.01% 1372
2016
Q2 		$3K Sell
564
-1,821
-76% -$6.33K ﹤0.01% 1341
2016
Q1 		$8K Sell
2,385
-547
-19% -$1.78K ﹤0.01% 1221
2015
Q4 		$10K Buy
+2,932
New +$11.6K ﹤0.01% 1244

Other funds holding NVET

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
LLC
Latimer Light Capital New York $432M AUM 25.5% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management's NVET Position: Q1 2017 in Review

Acadian Asset Management sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q1 2017, closing a stake of 564 shares — an estimated $2K sold.

Acadian Asset Management first reported a position in NVET in Q4 2015 and held it in 5 quarters. The position peaked at $10K in Q4 2015. 13 funds tracked by Wall St. Rank hold NVET as of Q1 2017.

  • Acadian Asset Management reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q1 2017 after selling out during the quarter.
  • Acadian Asset Management sold 564 Nexvet Biopharma plc Ordinary Shares shares in Q1 2017, an estimated $2K.
  • Acadian Asset Management first reported a position in Nexvet Biopharma plc Ordinary Shares in Q4 2015 and held it in 5 quarters.
  • Acadian Asset Management's Nexvet Biopharma plc Ordinary Shares position peaked at $10K in Q4 2015.
  • 13 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q1 2017.

Based on Acadian Asset Management's 13F filing for Q1 2017, filed 25 Apr 2017.